Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022273448> ?p ?o ?g. }
- W2022273448 endingPage "2236" @default.
- W2022273448 startingPage "2231" @default.
- W2022273448 abstract "Scientific and regulatory interest in assessing clinical endpoints after 48 to 72 h of treatment for acute bacterial skin and skin structure infections (ABSSSI) has increased. Historical, pre-antibiotic-era data suggest that a treatment effect relative to untreated controls can be discerned in this time interval. Ceftaroline fosamil, a broad-spectrum bactericidal cephalosporin with activity against Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA), and Gram-negative organisms was efficacious in two phase 3 trials of complicated skin infections (CANVAS 1 and 2) using clinical cure rates at the test-of-cure visit. To assess an early clinical response in the CANVAS trials, a retrospective analysis using a day 3 clinical endpoint was conducted. Adults with ABSSSI received intravenous ceftaroline fosamil at 600 mg every 12 h (q12h) or vancomycin at 1 g plus aztreonam at 1 g (V/A) q12h for 5 to 14 days. Clinical response at day 3, defined as cessation of infection spread and absence of fever, was analyzed in patients with a lesion size of ≥ 75 cm(2) and either deep and/or extensive cellulitis, major abscess, or an infected wound. Day 3 integrated CANVAS clinical response rates were 74.0% (296/400) for ceftaroline and 66.2% (263/397) for V/A (difference, 7.8%; 95% confidence interval [CI], 1.3% to 14.0%). In the individual studies, absolute treatment differences of 9.4% (CANVAS 1) and 5.9% (CANVAS 2) favoring ceftaroline were observed. For ABSSSI due to MRSA, response rates were 81.7% and 77.4% in the ceftaroline and V/A groups, respectively. In this retrospective analysis, ceftaroline fosamil monotherapy had a numerically higher clinical response than V/A at day 3 in the treatment of ABSSSI." @default.
- W2022273448 created "2016-06-24" @default.
- W2022273448 creator A5004602805 @default.
- W2022273448 creator A5005485120 @default.
- W2022273448 creator A5006319453 @default.
- W2022273448 creator A5031780287 @default.
- W2022273448 creator A5032773579 @default.
- W2022273448 creator A5053400330 @default.
- W2022273448 creator A5054829461 @default.
- W2022273448 creator A5058653363 @default.
- W2022273448 creator A5062255591 @default.
- W2022273448 creator A5082939573 @default.
- W2022273448 date "2012-05-01" @default.
- W2022273448 modified "2023-10-14" @default.
- W2022273448 title "CANVAS 1 and 2: Analysis of Clinical Response at Day 3 in Two Phase 3 Trials of Ceftaroline Fosamil versus Vancomycin plus Aztreonam in Treatment of Acute Bacterial Skin and Skin Structure Infections" @default.
- W2022273448 cites W1976915176 @default.
- W2022273448 cites W1996371082 @default.
- W2022273448 cites W2003449575 @default.
- W2022273448 cites W2015652530 @default.
- W2022273448 cites W2091382682 @default.
- W2022273448 cites W2118823941 @default.
- W2022273448 cites W2119808838 @default.
- W2022273448 cites W2122633654 @default.
- W2022273448 cites W2126237265 @default.
- W2022273448 cites W2131018144 @default.
- W2022273448 cites W2131834203 @default.
- W2022273448 cites W2155965882 @default.
- W2022273448 cites W2166778002 @default.
- W2022273448 cites W2168343206 @default.
- W2022273448 cites W2168593350 @default.
- W2022273448 cites W4237533259 @default.
- W2022273448 doi "https://doi.org/10.1128/aac.05738-11" @default.
- W2022273448 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3346585" @default.
- W2022273448 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22314524" @default.
- W2022273448 hasPublicationYear "2012" @default.
- W2022273448 type Work @default.
- W2022273448 sameAs 2022273448 @default.
- W2022273448 citedByCount "67" @default.
- W2022273448 countsByYear W20222734482012 @default.
- W2022273448 countsByYear W20222734482013 @default.
- W2022273448 countsByYear W20222734482014 @default.
- W2022273448 countsByYear W20222734482015 @default.
- W2022273448 countsByYear W20222734482016 @default.
- W2022273448 countsByYear W20222734482017 @default.
- W2022273448 countsByYear W20222734482018 @default.
- W2022273448 countsByYear W20222734482019 @default.
- W2022273448 countsByYear W20222734482020 @default.
- W2022273448 countsByYear W20222734482022 @default.
- W2022273448 crossrefType "journal-article" @default.
- W2022273448 hasAuthorship W2022273448A5004602805 @default.
- W2022273448 hasAuthorship W2022273448A5005485120 @default.
- W2022273448 hasAuthorship W2022273448A5006319453 @default.
- W2022273448 hasAuthorship W2022273448A5031780287 @default.
- W2022273448 hasAuthorship W2022273448A5032773579 @default.
- W2022273448 hasAuthorship W2022273448A5053400330 @default.
- W2022273448 hasAuthorship W2022273448A5054829461 @default.
- W2022273448 hasAuthorship W2022273448A5058653363 @default.
- W2022273448 hasAuthorship W2022273448A5062255591 @default.
- W2022273448 hasAuthorship W2022273448A5082939573 @default.
- W2022273448 hasBestOaLocation W20222734481 @default.
- W2022273448 hasConcept C126322002 @default.
- W2022273448 hasConcept C141071460 @default.
- W2022273448 hasConcept C203092338 @default.
- W2022273448 hasConcept C2777052132 @default.
- W2022273448 hasConcept C2777238321 @default.
- W2022273448 hasConcept C2778980435 @default.
- W2022273448 hasConcept C2779489039 @default.
- W2022273448 hasConcept C2779631663 @default.
- W2022273448 hasConcept C2780416669 @default.
- W2022273448 hasConcept C2908866784 @default.
- W2022273448 hasConcept C44249647 @default.
- W2022273448 hasConcept C501593827 @default.
- W2022273448 hasConcept C523546767 @default.
- W2022273448 hasConcept C535046627 @default.
- W2022273448 hasConcept C54355233 @default.
- W2022273448 hasConcept C71924100 @default.
- W2022273448 hasConcept C86803240 @default.
- W2022273448 hasConcept C89423630 @default.
- W2022273448 hasConcept C90924648 @default.
- W2022273448 hasConcept C94665300 @default.
- W2022273448 hasConceptScore W2022273448C126322002 @default.
- W2022273448 hasConceptScore W2022273448C141071460 @default.
- W2022273448 hasConceptScore W2022273448C203092338 @default.
- W2022273448 hasConceptScore W2022273448C2777052132 @default.
- W2022273448 hasConceptScore W2022273448C2777238321 @default.
- W2022273448 hasConceptScore W2022273448C2778980435 @default.
- W2022273448 hasConceptScore W2022273448C2779489039 @default.
- W2022273448 hasConceptScore W2022273448C2779631663 @default.
- W2022273448 hasConceptScore W2022273448C2780416669 @default.
- W2022273448 hasConceptScore W2022273448C2908866784 @default.
- W2022273448 hasConceptScore W2022273448C44249647 @default.
- W2022273448 hasConceptScore W2022273448C501593827 @default.
- W2022273448 hasConceptScore W2022273448C523546767 @default.
- W2022273448 hasConceptScore W2022273448C535046627 @default.
- W2022273448 hasConceptScore W2022273448C54355233 @default.
- W2022273448 hasConceptScore W2022273448C71924100 @default.
- W2022273448 hasConceptScore W2022273448C86803240 @default.
- W2022273448 hasConceptScore W2022273448C89423630 @default.